Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
Avanir and Otsuka have always shared a deep commitment to advancing solutions that improve the lives of patients by Nuedexta (dextromethorphan hydrobromide and quinidine sulfate).
Lead Product(s): Deudextromethorphan Hydrobromide,Quinidine sulphate
Therapeutic Area: Neurology Product Name: AVP-786
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Otsuka America Pharmaceutical, Inc.
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Merger October 24, 2022